27491778|t|Beneficial effects of dark chocolate on exercise capacity in sedentary subjects: underlying mechanisms. A double blind, randomized, placebo controlled trial
27491778|a|In heart failure patients the consumption of (-)-epicatechin ((-)-Epi)-rich cocoa can restore skeletal muscle (SkM) mitochondrial structure and decrease biomarkers of oxidative stress. However, nothing is known about its effects on exercise capacity and underlying mechanisms in normal, sedentary subjects. Twenty normal, sedentary subjects (∼50 years old) were randomized to placebo or dark chocolate (DC) groups and consumed 20 g of the products for 3 months. Subjects underwent before and after treatment, bicycle ergometry to assess VO2 max and work, SkM biopsy to assess changes in mitochondrial density, function and oxidative stress and blood sampling to assess metabolic endpoints. Seventeen subjects completed the trial. In the DC group (n = 9), VO2 max increased (17% increase, p = 0.056) as well as maximum work (watts) achieved (p = 0.026) with no changes with placebo (n = 8). The DC group evidenced increases in HDL levels (p = 0.005) and decreased triglycerides (p = 0.07). With DC, SkM evidenced significant increases in protein levels for LKB1, AMPK and PGC1α and in their active forms (phosphorylated AMPK and LKB1) as well as in citrate synthase activity while no changes were observed in mitochondrial density. With DC, significant increases in SkM reduced glutathione levels and decreases in protein carbonylation were observed. Improvements in maximum work achieved and VO2 max may be due to DC activation of upstream control systems and enhancement of SkM mitochondria efficiency. Larger clinical studies are warranted to confirm these observations.
27491778	0	10	Beneficial	T081	C0814225
27491778	11	18	effects	T080	C1280500
27491778	22	36	dark chocolate	T168	C3853217
27491778	40	48	exercise	T056	C0015259
27491778	49	57	capacity	T081	C1516240
27491778	61	70	sedentary	T080	C0205254
27491778	71	79	subjects	T098	C2349001
27491778	92	102	mechanisms	T169	C0441712
27491778	106	118	double blind	T062	C0013072
27491778	120	130	randomized	T062	C0034656
27491778	132	150	placebo controlled	T062	C1706408
27491778	151	156	trial	T062	C0008976
27491778	160	173	heart failure	T047	C0018801
27491778	174	182	patients	T101	C0030705
27491778	187	198	consumption	T039	C1947907
27491778	202	217	(-)-epicatechin	T121	C1881340
27491778	219	226	(-)-Epi	T121	C1881340
27491778	233	238	cocoa	T168	C0009209
27491778	251	266	skeletal muscle	T024	C0242692
27491778	268	271	SkM	T024	C0242692
27491778	273	286	mitochondrial	T026	C0026237
27491778	287	296	structure	T082	C0678594
27491778	301	309	decrease	T081	C0547047
27491778	310	320	biomarkers	T201	C0005516
27491778	324	340	oxidative stress	T049	C0242606
27491778	378	385	effects	T080	C1280500
27491778	389	397	exercise	T056	C0015259
27491778	398	406	capacity	T081	C1516240
27491778	422	432	mechanisms	T169	C0441712
27491778	436	442	normal	T080	C0205307
27491778	444	453	sedentary	T080	C0205254
27491778	454	462	subjects	T098	C2349001
27491778	471	477	normal	T080	C0205307
27491778	479	488	sedentary	T080	C0205254
27491778	489	497	subjects	T098	C2349001
27491778	503	512	years old	T100	C0001675
27491778	519	529	randomized	T062	C0034656
27491778	533	540	placebo	T061	C0032042
27491778	544	558	dark chocolate	T168	C3853217
27491778	560	562	DC	T168	C3853217
27491778	564	570	groups	T078	C0441833
27491778	575	583	consumed	T052	C2983605
27491778	611	617	months	T079	C0439231
27491778	619	627	Subjects	T098	C2349001
27491778	655	664	treatment	T061	C0087111
27491778	666	683	bicycle ergometry	T060	C0857787
27491778	687	693	assess	T058	C0184514
27491778	694	701	VO2 max	T033	C0429693
27491778	706	710	work	T057	C0043227
27491778	712	722	SkM biopsy	T060	C2315740
27491778	726	732	assess	T058	C0184514
27491778	744	757	mitochondrial	T026	C0026237
27491778	758	765	density	T081	C0178587
27491778	767	775	function	T169	C0542341
27491778	780	796	oxidative stress	T049	C0242606
27491778	801	815	blood sampling	T060	C0005834
27491778	819	825	assess	T058	C0184514
27491778	826	835	metabolic	T169	C0311400
27491778	836	845	endpoints	T080	C2349179
27491778	857	865	subjects	T098	C2349001
27491778	880	885	trial	T062	C0008976
27491778	894	896	DC	T168	C3853217
27491778	912	919	VO2 max	T033	C0429693
27491778	920	929	increased	T169	C0442805
27491778	935	943	increase	T169	C0442805
27491778	975	979	work	T057	C0043227
27491778	981	986	watts	T081	C0439261
27491778	1030	1037	placebo	T061	C0032042
27491778	1051	1053	DC	T168	C3853217
27491778	1070	1079	increases	T169	C0442805
27491778	1083	1086	HDL	T116,T123	C0023821
27491778	1110	1119	decreased	T081	C0205216
27491778	1120	1133	triglycerides	T109,T123	C0041004
27491778	1151	1153	DC	T168	C3853217
27491778	1155	1158	SkM	T024	C0242692
27491778	1169	1180	significant	T078	C0750502
27491778	1181	1190	increases	T169	C0442805
27491778	1194	1201	protein	T116,T123	C0033684
27491778	1213	1217	LKB1	T116,T126	C1431123
27491778	1219	1223	AMPK	T116,T126	C2350345
27491778	1228	1233	PGC1α	T116,T123	C1452082
27491778	1247	1253	active	T169	C0205177
27491778	1261	1275	phosphorylated	T044	C0031715
27491778	1276	1280	AMPK	T116,T126	C2350345
27491778	1285	1289	LKB1	T116,T126	C1431123
27491778	1305	1330	citrate synthase activity	T044	C2258114
27491778	1365	1378	mitochondrial	T026	C0026237
27491778	1379	1386	density	T081	C0178587
27491778	1393	1395	DC	T168	C3853217
27491778	1397	1408	significant	T078	C0750502
27491778	1409	1418	increases	T169	C0442805
27491778	1422	1425	SkM	T024	C0242692
27491778	1434	1445	glutathione	T116,T123	C0017817
27491778	1457	1466	decreases	T081	C0547047
27491778	1470	1491	protein carbonylation	T044	C1563721
27491778	1531	1535	work	T057	C0043227
27491778	1549	1556	VO2 max	T033	C0429693
27491778	1571	1573	DC	T168	C3853217
27491778	1574	1584	activation	T052	C1879547
27491778	1632	1635	SkM	T024	C0242692
27491778	1636	1648	mitochondria	T026	C0026237
27491778	1649	1659	efficiency	T081	C0013682
27491778	1668	1684	clinical studies	T062	C0008972
27491778	1716	1728	observations	T062	C0302523